Printer Friendly

Printed from http://www.researchandmarkets.com/reports/2114511

Peptic Ulcers - Pipeline Review, H1 2012

Description:

Peptic Ulcers – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Peptic Ulcers - Pipeline Review, H1 2012', provides an overview of the Peptic Ulcers therapeutic pipeline. This report provides information on the therapeutic development for Peptic Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peptic Ulcers. 'Peptic Ulcers - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Peptic Ulcers.
- A review of the Peptic Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Peptic Ulcers pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Peptic Ulcers.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Peptic Ulcers pipeline depth and focus of Peptic Ulcers therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Peptic Ulcers Therapeutic Products under Development, Key Players in Peptic Ulcers Therapeutics, Peptic Ulcers Pipeline Overview, Peptic Ulcers Pipeline, Peptic Ulcers Pipeline Assessment

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Peptic Ulcers Overview
Therapeutics Development
An Overview of Pipeline Products for Peptic Ulcers
Peptic Ulcers Therapeutics under Development by Companies
Peptic Ulcers Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Peptic Ulcers Therapeutics – Products under Development by Companies
Peptic Ulcers Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Peptic Ulcers Therapeutics Development
Sequella, Inc.
AstraZeneca PLC
Takeda Pharmaceutical Company Limited
Daewoong Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
POZEN Inc.
aRigen Pharmaceuticals, Inc.
Vecta Ltd.
Medigreen Biotechnology Corporation
Peptic Ulcers – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
TAK-438 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMD4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DWJ206 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aciphex Extended Release - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nexium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SQ 109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PA32540 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARH-1029 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vecam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Axanum - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rabeprazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Esomeprazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lansoprazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MIC-31 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptic Ulcers Therapeutics – Drug Profile Updates
Peptic Ulcers Therapeutics – Discontinued Products
Peptic Ulcers Therapeutics - Dormant Products
Peptic Ulcers – Product Development Milestones
Featured News & Press Releases
Mar 29, 2012: Covis's Zantac Injection Returns To Market
Mar 29, 2012: Covis's Zantac Injection Returns To Market
Mar 22, 2012: POZEN Announces Positive Top-Line Results From Two Pivotal Phase III Studies Of PA32540
Oct 24, 2011: Daiichi Sankyo And AstraZeneca Apply For Additional Indication In Japan For NEXIUM 10mg And 20mg Capsules
Oct 24, 2011: Daiichi Sankyo And AstraZeneca Apply For Additional Indication In Japan For NEXIUM 10mg And 20mg Capsules
Oct 24, 2011: Daiichi Sankyo And AstraZeneca Apply For Additional Indication In Japan For NEXIUM 10mg And 20mg Capsules
Oct 13, 2011: POZEN Reports Top-Line Results From Long-Term Phase III Safety Study Of PA32540
Oct 13, 2011: POZEN Reports Top-Line Results From Long-Term Phase III Safety Study Of PA32540
Sep 16, 2011: Takeda's TAK-438 Enters Into Phase III Clinical Trials In Japan For Treatment Of Acid-Related Diseases
Sep 16, 2011: Takeda's TAK-438 Enters Into Phase III Clinical Trials In Japan For Treatment Of Acid-Related Diseases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Peptic Ulcers, H1 2012
Products under Development for Peptic Ulcers – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Sequella, Inc., H1 2012
AstraZeneca PLC, H1 2012
Takeda Pharmaceutical Company Limited, H1 2012
Daewoong Pharmaceutical Co., Ltd., H1 2012
Eisai Co., Ltd., H1 2012
POZEN Inc., H1 2012
aRigen Pharmaceuticals, Inc., H1 2012
Vecta Ltd., H1 2012
Medigreen Biotechnology Corporation, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Peptic Ulcers Therapeutics – Drug Profile Updates
Peptic Ulcers Therapeutics – Discontinued Products
Peptic Ulcers Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Peptic Ulcers, H1 2012
Products under Development for Peptic Ulcers – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2

Printed Monday, May 20, 2013
5:58:02 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Peptic Ulcers - Pipeline Review, H1 2012

Web Address

http://www.researchandmarkets.com/reports/2114511

Office Code

OC8DIQSRLNWQVR

Report Formats

Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Single User		EURO€ 384.00
Electronic (PDF) - Site License		EURO€ 769.00
Electronic (PDF) - Enterprisewide		EURO€ 1,153.00

Contact information

Please enter all the information below in block capitals.

                Title:
            
                    Mr
                    
                    Mrs
                    
                    Dr
                    
                    Miss
                    
                    Ms
                    
                    Prof
                    
                First Name:
            
                Last Name:
                
                Email Address:
            
                Job Title:
            
                Organisation:
            
                Address:
            
                City:
            
                Postal / Zip Code:	
            
                Country:	
            
                Phone Number:	
            
                Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2

Printed Monday, May 20, 2013
5:58:02 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:

Cardholder's Signature:

Expiry Date:

Card Number:

CVV Security Code:

Issue date:

(Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:

83313083

Sort Code:

98-53-30

Swift Code:

ULSBIE2D

IBAN Number:

IE78ULSB98533083313083

Bank Address:

Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Printer Friendly

Peptic Ulcers - Pipeline Review, H1 2012

Fax order form

Order information

Product name

Web Address

Office Code

Report Formats

Contact information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Payment information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)